Weave
Weave Bio is an AI-native, cloud-based, software company redesigning regulatory workflows and transforming how novel therapies navigate the complex path from lab to market. The Weave Platform is an end-to-end solution that streamlines regulatory content preparation and lifecycle management for pharmaceutical companies, biotech firms, CROs, and regulatory consultants. Weave infuses AI into every step of the workflow, from data extraction to authoring to review and data verification, to yield compliant, submission-ready regulatory dossiers with unprecedented speed. The Weave Platform has been widely adopted for preclinical IND preparation and earned industry recognition as the “Biotech AI Innovation of the Year” award winner. Weave Bio has since expanded platform capabilities across the platform to encompass clinical and approval-stage submissions, delivering a comprehensive AI workbench that accelerates regulatory timelines by more than 50% while improving review quality and ensuring compliance with FDA, EMA, and global regulatory standards. Founded in 2022 and headquartered in San Francisco, Weave bridges life sciences, regulatory expertise, AI innovation, and enterprise software to solve critical bottlenecks in drug development.
HQ: San Francisco, California, United States
Country: USA

Establishment Year:
2023

Company Stage:
Initial Revenues

Estimated Employees:
11 .. 50

Estimated Revenues
$M 2.00

Raised Funding:
$M 43.00

AI Categories: